Paper Details

  1. Home
  2. Paper Details

Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data.

Author: FriedlanderMichael, LeeYeh Chen, TewWilliam P

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This review discusses the differences and management strategies for adverse side effects of poly (ADP-ribose) polymerase (PARP) inhibitors, which are standard care for various malignancies. The three approved PARP inhibitors (olaparib, niraparib, rucaparib) share common adverse effects, but differences likely arise from variations in their poly-pharmacology and off-target effects.
Paper Details　
Original Abstract of the Article :
The use of poly (ADP-ribose) polymerase (PARP) inhibitor therapy is standard care in the management of patients with various malignancies including ovarian, breast, prostate, and pancreatic cancers. PARP inhibitors have been approved in different settings for patients with specific hereditary pathog...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/EDBK_390876

データ提供：米国国立医学図書館（NLM）

Managing Adverse Effects of PARP Inhibitors in Ovarian Cancer

This study explores the evolving landscape of cancer treatment, where new medications are constantly being developed and evaluated. The researchers investigate the management of adverse effects associated with PARP inhibitors, a class of drugs used to treat ovarian cancer.

The study highlights the common adverse effects of PARP inhibitors, such as nausea, fatigue, and anemia, and discusses strategies for mitigating and managing these complications. It also emphasizes the importance of considering individual patient factors, such as performance status and comorbidities, when assessing the potential benefits and risks of these medications.

This research provides valuable insights into the management of PARP inhibitor therapy in ovarian cancer, offering guidance for healthcare providers and patients.

Navigating the Desert of Cancer Treatment

This study provides a valuable guide for navigating the desert of cancer treatment, where every step can be challenging and unpredictable. It reminds us that while new medications offer hope, we must also be prepared to manage their potential side effects.

Living a Strong Life in the Face of Cancer

Cancer treatment can be a long and arduous journey, but it's important to remember that there are resources and support available to help patients navigate this challenging landscape. Working with healthcare professionals, connecting with support groups, and making healthy lifestyle choices can help patients maintain their strength and resilience.

Dr.Camel's Conclusion

This research underscores the importance of careful monitoring and effective management of adverse effects when prescribing PARP inhibitors. It reminds us that the desert of cancer treatment requires a comprehensive approach, with a focus on both the benefits and potential risks of various therapies.

Date :
  1. Date Completed 2023-06-09
  2. Date Revised 2023-06-09
Further Info :

Pubmed ID

37285556

DOI: Digital Object Identifier

10.1200/EDBK_390876

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.